Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

JCR Pharma (4552 JP): Contract Revenue, Izcargo Comes To Rescue in Q1FY27, FY27 Guidance Reiterated

JCR Pharma (4552 JP): Izcargo Holds Revenue As Price Revision Impacts Growject; Guidance Reiterated

JCR Pharmaceutical (4552 JP): Licensing Income Boosts H1FY26 Overall Performance; What Lies Ahead

JCR Pharma (4552 JP): Contractual Payments Boost 9MFY26 Revenue; Profit Guidance Revised Downwards

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/jcr-pharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:20126:1" rel="noopener">Jcr Pharmaceuticals (4552 JP)</a> revenue increased 22% to ¥40.3B in FY26, mainly driven by Izcargo and contractual payments, marred to an extent by NHI price revision impact on Growject.</li>
<li>FY27 guidance expects revenue to be ¥45.7B (+13% YoY). Operating income expected to be ¥1.1B (up 98% YoY) and net income ¥200M, down YoY, sans the extraordinary gains like FY26.</li>
<li>JCR’s two pipeline drugs are under Phase III trials: pabinafusp alfa (JR-141) for Hunter syndrome and JR-142, for growth hormone deficiency. Approvals not expected before FY28.</li>
</ul>



Jcr Pharmaceuticals (4552 JP) revenue increased 22% to ¥40.3B in FY26, mainly driven by Izcargo and contractual payments, marred to an extent by NHI price revision impact on Growject.
FY27 guidance expects revenue to be ¥45.7B (+13% YoY). Operating income expected to be ¥1.1B (up 98% YoY) and net income ¥200M, down YoY, sans the extraordinary gains like FY26.
JCR’s two pipeline drugs are under Phase III trials: pabinafusp alfa (JR-141) for Hunter syndrome and JR-142, for growth hormone deficiency. Approvals not expected before FY28.


JCR Pharma (4552 JP): FY26 Seen Off On Contractual Payments, Not Enough Strong Firepower Visible Yet